Evidence map›Paper›PMID 40442465›Full record

ReviewAnnals of surgical oncology2025

Ablative Therapies in Low-Risk Thyroid Cancer.

Yinin Hu, Lauren N Krumeich, Sarah B Fisher, Mahsa Javid, Jennifer H Kuo, Heather Wachtel

Abstract readReview
PubMed Publisher
In one paragraph

Review in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yinin HuUniversity of Maryland Baltimore, Baltimore, MD, USA. yinin.hu@som.umaryland.edu.
Lauren N KrumeichUniversity of Michigan, Ann Arbor, MI, USA.
Sarah B FisherM.D. Anderson Cancer Center, Houston, TX, USA.
Mahsa JavidUniversity of Louisville, Louisville, KY, USA.
Jennifer H KuoColumbia University Medical Center, New York, NY, USA.
Heather WachtelPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Funding

NCI NIH HHS #K08 CA270385NCI NIH HHS #K08 CA293167
6 · The paper itself

Abstract

Treatment pathways for low-risk thyroid cancer have seen broad de-escalation over the past two decades. A condition once treated predominantly with total thyroidectomy with selective adjuvant radioactive iodine is now frequently treated with partial thyroidectomy alone or even active surveillance among carefully selected patients. Over the same period, percutaneous ablative treatment for benign thyroid nodules has expanded. Inevitably, there evolved a growing interest in the application of ablative therapy to lowrisk thyroid cancer as an intermediate option between surveillance and resection. This article introduces the most common modalities for percutaneous ablation of thyroid cancer, summarizes contemporary evidence, highlights gaps in knowledge, and proposes a set of real-world practice recommendations.

Indexed as

Ablation TechniquesRadiofrequency AblationThyroid NeoplasmsHumansIodine RadioisotopesPrognosisThyroidectomyIodine RadioisotopesCervical lymph node ablationPercutaneous ablationThyroid ablationThyroid cancer

Identifiers

PMID40442465

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.